Helix BioPharma makes two appointments
Jack Kay as chairman and Professor Kazimierz Roszkowski-Sliz as European Medical Director
Helix has also hired Professor Kazimierz Roszkowski-Śliż as European Medical Director, to provide critical oversight and direction for Helix’s upcoming European L-DOS47 clinical programme.
Kay has been a director of Helix since 2005. He has worked in the pharmaceutical industry for more than 45 years, and since 1995 has been president of Apotex.
Professor Roszkowski-Śliż is an expert in the field of lung disease and lung cancers, and is a director at the National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland, where he is also head of the clinical department.
You may also like
Research & Development
Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs
Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments